Cellular therapy: Exploiting NK cell alloreactivity in transplantation

Current Opinion in Hematology

Volumn 8, Issue 6, 2001, Pages 355-359

  Ruggeri, Loredana ^a   Capanni, Marusca ^a   Martelli, Massimo F ^a   Velardi, Andrea ^a,b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b POLICLINICO MONTELUCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ADOPTIVE IMMUNOTHERAPY; ALLOGRAFT; ALLOIMMUNITY; GRAFT VERSUS HOST REACTION; HAPLOTYPE; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; LEUKEMIA; MAJOR HISTOCOMPATIBILITY COMPLEX; NATURAL KILLER CELL; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; T LYMPHOCYTE ACTIVATION;

ANIMALS; GRAFT VS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE DEPLETION; TRANSPLANTATION, HOMOLOGOUS;

EID: 0034754603     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-200111000-00007     Document Type: Review

References (35)

1. CD8+ minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells
2. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia
3. Transplantation for severe combined immunodeficiency with HLA-A, B, D, DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells
4. Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice
5. Successful engraftment of T-cell-depleted haploidentical "three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum
6. Transplantation for high-risk acute leukemia with high doses of T cell-depleted hematopoietic stem cells from haploidentical "three loci" incompatible donors
7. Stem cell escalation enables HLA-disparate haematopoietic transplants in leukaemia patients
8. HLA class I specific inhibitory receptors
9. Killer cell receptors: Keeping pace with MHC class I evolution
10. NK receptors
11. Specific lysis of allogeneic cells after activation of CD3-lymphocytes in mixed lymphocyte culture
12. Specific recognition of human CD3-/CD16+ natural killer cells requires the expression of an autosomic recessive gene on target cells
13. Evidence of a natural killer (NK) cell repertoire for (allo) antigen recognition: Definition of five distinct NK-determined allospecificities in humans
14. Involvement of HLA class I alleles in natural killer (NK) cell-specific functions: Expression of HLA-Cw3 confers selective protection from lysis by alloreactive NK clones displaying a defined specificity (specificity 2)
15. Generation of allospecific natural killer cells by stimulation across a polymorphism of HLA-C
16. HLA-C is the inhibitory ligand that determines dominant resistance to lysis by NK1- and NK2-specific natural killer cells
17. The role of Ly49A and 5E6 (Ly49C) molecules in hybrid resistance mediated by murine natural killer cells against normal T cell blasts
18. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation
19. KIR epitope incompatibility in the graft-vs-host direction predicts control of leukemia relapse after mismatched hematopoietic transplantation
20. Peculiar immunobiology of bone marrow allografts: Rejection of parental grafts by F1 hybrid mice
21. Mini mismatched transplantation in the mouse by the use of alloreactive NK cells for conditioning
22. Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment
23. Induction of donor-type chimerism and transplantation tolerance across major histocompatibility barriers in sublethally irradiated mice by Sca-1 (+)Lin(-) bone marrow progenitor cells: Synergism with non-alloreactive (host x donor) F(1) T cells
24. Anti-third party CD8+ CTLs as potent veto cells: Coexpression of CD8 and FasL is a prerequisite
25. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy
26. Non-myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non-malignant hematologic diseases
27. Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies
28. Intentional induction of mixed chimerism andachievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies
29. Mini-allografts: Ongoing trials in humans
30. Melphalan and purine analog-containing preparative regimens: Reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation
31. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions
32. Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects
33. Bone marrow transplantation in adult thalassemic patients
34. Bone marrow transplantation from alternative donors for thalassemia: HLA-phenotypically identical relative and HLA-nonidentical sibling or parent transplants